| |
|
| {{customText[Uncover BPDCN|BPDCN may be more common than you think| Consider BPDCN, an aggressive hematologic cancer]}} |
|
|
|
|
| |
|
| Dear {{accFname}} {{accLname}}, |
|
| {{customText[Before our upcoming meeting, I wanted to share some information about blastic plasmacytoid dendritic cell neoplasm (BPDCN) and how to identify it. I look forward to sharing more information with you about this deadly hematologic disease.|Thank you for taking the time to speak with me about blastic plasmacytoid dendritic cell neoplasm (BPDCN). Summarized below are the key points from our discussion about BPDCN. Please let me know if you have any additional questions. I will reach out to schedule another time to meet.|I’m sorry we missed each other, but I hope we’ll soon have the chance to discuss blastic plasmacytoid dendritic cell neoplasm (BPDCN). In the meantime, here is some important information about BPDCN and how to identify it in your patients. I will reach out again to see if we can find a convenient time to meet, or please feel free to reach out with your availability. I'll be happy to work around your schedule.]}} |
|
| {{customText[Best regards,|Thank you,|Until then,]}} |
|
| {{userName}} |
|
| {{user.Title}} |
|
| {{userEmailAddress}} |
|
| {{user.Phone}} |
|
| Stemline Therapeutics, Inc. |
|
|
|
|
 |
COULD THE
HEMATOLOGIC
CANCER YOU
JUST DIAGNOSED...
ACTUALLY BE BPDCN?
What the CD123 diagnostic marker
can tell you* |
|
|
| |
CD123 SHOULD BE ADDED TO INITIAL
HEMATOLOGIC DIAGNOSTIC PANELS.1 |
|
|
| What is BPDCN? |
|
| • |
BPDCN is a highly aggressive hematologic cancer1 |
|
|
| • |
Frequent reclassification and renaming has contributed to the underrecognition of BPDCN1 |
|
|
| • |
Sites of involvement include1-3 |
|
|
|
— |
Primary: bone marrow, peripheral blood, skin |
|
— |
Secondary: lymph nodes, viscera |
|
|
| • |
Early and accurate diagnosis is critical to proper management of patients with BPDCN4 |
|
|
| • |
BPDCN exhibits variable dermatologic and hematologic presentation3,5-8 |
|
|
|
— |
~85% to 90% of patients with BPDCN present with skin lesions |
|
— |
~60% to 90% of patients present with leukemic disease |
|
|
| BPDCN MAY BE MISTAKEN FOR1,3,6,9 |
|
|
|
|
| BPDCN = blastic plasmacytoid dendritic cell neoplasm; AML = acute myeloid leukemia; NHL = non-Hodgkin’s lymphoma; ALL = acute lymphoblastic leukemia; MDS = myelodysplastic syndrome; CMML = chronic myelomonocytic leukemia. |
|
|
*BPDCN diagnosis can include other markers, such as CD4, CD56, TCL1, and CD303 (BDCA2).1
|
|
|
| Diagnosing BPDCN |
|
| • |
The signature marker triad CD123, CD4, CD56 allows for proper diagnosis of BPDCN1,10 |
|
|
| • |
CD123 is rapidly emerging as a therapeutic target in hematologic cancer1 |
|
|
| • |
Key features of CD123 expression4,6,10,11 |
|
|
|
— |
Highly expressed on BPDCN cells (~95%) and negligibly expressed on healthy cells |
|
— |
Can be identified through any biopsy of malignant cells |
|
— |
Can be both a diagnostic marker and a therapeutic target in BPDCN |
|
|
Visit BPDCNinfo.com for more information
about diagnosing BPDCN. |
|
| References: 1. Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188-202. 2. Reichard KK. Blastic plasmacytoid dendritic cell neoplasm: how do you distinguish it from acute myeloid leukemia? Surg Pathol Clin. 2013;6(4):743-765. 3. Riaz W, Zhang L, Horna P, Sokol L. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control. 2014;21(4):279-289. 4. Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385-392. 5. Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology Am Soc Hematol Educ Program. 2016;2016(1):16-23. 6. Laribi K, Denizon N, Besançon A, et al. Blastic plasmacytoid dendritic cell neoplasm: from origin of the cell to targeted therapies. Biol Blood Marrow Transplant. 2016;22(8):1357-1367. 7. Julia F, Petrella T, Beylot-Barry M, et al. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol. 2013;169(3):579-586. 8. Herling M, Jones D. CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol. 2007;127(5):687-700. 9. León-Martínez G, Meillón-García L, Morales-Polanco M, Soler-Montecinos L, Ortiz-Hidalgo C. Unusual morphologic presentations of blastic plasmacytoid dendritic cell neoplasm: report of two cases misdiagnosed as melanoma and leprosy. Int J Surg Pathol. 2014;22(1):76-82. 10. Pemmaraju N, Konopleva M. Treating blastic plasmacytoid dendritic cell neoplasm. The Hematologist website. http://www.hematology.org/Thehematologist/Ask/8927.aspx. Published August 28, 2018. Accessed February 14, 2019. 11. Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S, Vermi W. Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol. 2016;29(2):98-111. |
|
|
|
|
|
| If you do not wish to receive promotional emails from Stemline Therapeutics, Inc., click here. |
|
|
|
|
|
|
|
|
| |
|
